GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Day One
Day One Biopharmaceuticals specializes in developing drugs to treat childhood cancer. Its stock price reflects both the enormous social impact of its work and the binary risks associated with clinical trials in this complex area of medicine.
Share prices of companies in the market segment - General oncology therapy
Day One Biopharmaceuticals focuses on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages. We've categorized it as a "General Oncology" company. The chart below shows how the market values biotech companies fighting cancer.
Broad Market Index - GURU.Markets
Day One Biopharmaceuticals focuses on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
DAWN - Daily change in the company's share price Day One
Shares of Day One, an oncology company focused on childhood cancer, are highly volatile. Change_co measures the market's reaction to clinical trial data. This metric is an important component of formulas on System.GURU.Markets that evaluate biotech companies in niche sectors.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Day One Biopharmaceuticals, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with DAWN, which focuses on pediatric cancer treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Day One is a biopharmaceutical company specializing in cancer treatments for children and adults. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating Day One stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Day One
Day One is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are teetering on the edge of anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Day One Biopharmaceuticals, Inc. is a commercial biopharmaceutical company focused on developing and commercializing targeted therapies for the treatment of pediatric and adult cancers. This chart shows how its commercialization success and clinical trial results impact its performance in the oncology sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Day One Biopharmaceuticals is a biopharmaceutical company whose stock performance is driven by the commercialization of its drugs and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Day One
HomeTrust, a bank operating in North Carolina and neighboring states, has monthly fluctuations that reflect the economic health of this fast-growing region and the dynamics of the local commercial and mortgage lending markets, making it a barometer of the local economy.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Day One Biopharmaceuticals specializes in developing cancer treatments for children and young adults, occupying an important but narrow niche in oncology. The dynamics of this biotech segment are highly dependent on clinical trial results and regulatory decisions. The chart shows how investors generally assessed the prospects of targeted therapy for specific patient groups.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Day One Biopharmaceuticals is focused on developing treatments for childhood cancer. It's a biotech company with a strong social mission. Its stock moves based on clinical trial results. Investors are betting on a scientific breakthrough in one of the most complex areas of medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Day One
Day One Biopharmaceuticals focuses on developing treatments for pediatric cancer. Its weekly stock price is highly volatile and heavily dependent on clinical trial results and regulatory decisions, reflecting the high risks and social significance of its mission.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Day One Biopharmaceuticals is a company focused on pediatric oncology. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart shows how news about its clinical trials drives share prices independent of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Day One, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
DAWN - Market capitalization of the company Day One
Day One Biopharmaceuticals' market capitalization is a story focused on treating childhood cancer. The company's chart reflects investor expectations for its targeted drugs for specific genetic mutations in children. Its dynamics visualize how the market perceives the potential in this complex yet socially significant area of oncology.
DAWN - Share of the company's market capitalization Day One within the market segment - General oncology therapy
Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for cancer patients of all ages, with a particular focus on pediatric oncology. Its market share reflects its hopes for breakthroughs in this complex and important field. The chart below demonstrates the market's confidence in its mission.
Market capitalization of the market segment - General oncology therapy
Day One Biopharmaceuticals focuses on developing cancer treatments for children and adults with genetically defined tumors. The chart below shows the overall market capitalization of the oncology sector. It reflects the importance and complexity of developing targeted therapies for specific patient groups, where Day One excels.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a glimpse of hope for children with cancer. Day One Biopharmaceuticals focuses on developing targeted therapies for pediatric oncology. Its volatile line on the chart reflects clinical trial results, a visualization of how science is fighting for the lives of our youngest patients.
Book value capitalization of the company, segment and market as a whole
DAWN - Book value capitalization of the company Day One
Day One Biopharmaceuticals' capital is its financial reserves and intellectual property for pediatric cancer drugs. Its book value represents its monetary and scientific resources for fighting rare diseases. The chart shows how the company manages its budget to accelerate the development and commercialization of life-saving drugs.
DAWN - Share of the company's book capitalization Day One within the market segment - General oncology therapy
Day One is a biotech company focused on developing cancer treatments for children and adults. Its assets are intellectual property and a team of scientists. The chart shows a minimal share of physical assets, as its value lies in the potential of its drugs, not its manufacturing facilities.
Market segment balance sheet capitalization - General oncology therapy
Developing pediatric oncology treatments like Day One's is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Day One Biopharmaceuticals' assets are not plants, but capital and intellectual property focused on developing drugs to treat childhood cancer. The book value reflects the financial resources available to conduct clinical trials in this complex and important area of medicine. The chart demonstrates the scale of this ambitious biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Day One
For Day One, which develops treatments for childhood cancer, market capitalization is a bet on the success of its drugs. The ratio to book value (its cash) reflects how much the market values its noble mission and believes in the commercial potential of its developments.
Market to book capitalization ratio in a market segment - General oncology therapy
Day One Biopharmaceuticals specializes in developing cancer treatments for children and adolescents. This is a socially significant yet complex niche. The high valuation on the chart reflects investors' faith in the potential of its drugs and the importance of the company's mission.
Market to book capitalization ratio for the market as a whole
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages, with a particular focus on pediatric patients. Its valuation is a bet on success in this important and complex niche of oncology. This metric demonstrates how the market values companies solving specific but significant medical problems.
Debts of the company, segment and market as a whole
DAWN - Company debts Day One
Day One Biopharmaceuticals, focused on developing pediatric cancer treatments, is raising capital to fund its clinical trials. For such a socially important yet niche company, access to equity and debt financing is vital to bringing drugs to patients. This chart illustrates the high cost of such developments.
Market segment debts - General oncology therapy
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for cancer treatment in patients of all ages, with a particular focus on pediatric oncology. This chart shows how the biotech company funds its clinical trials and prepares to launch its first drug, which requires significant capital investment.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Day One
Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies to treat cancer in patients of all ages, with a particular focus on pediatric oncology. Clinical trials are a long and expensive process. This chart shows how the company uses debt to fund its vital, yet risky, research.
Market segment debt to market segment book capitalization - General oncology therapy
Day One Biopharmaceuticals focuses on developing cancer treatments for children and young adults, a socially important yet complex niche in oncology. This chart shows how the company finances its clinical trials. It relates its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Day One Biopharmaceuticals aims to develop cancer treatments for children and young adults. This is a socially important, yet complex and expensive, area of pharmaceuticals. How dependent is the company on debt to finance its clinical trials? This graph of total debt in the economy allows us to assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - Day One
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages, with a particular focus on pediatric oncology. This chart shows how investors view its humanitarian mission and commercial potential. This assessment is based on clinical trial success.
P/E of the market segment - General oncology therapy
Day One Biopharmaceuticals specializes in developing and commercializing targeted therapies for patients of all ages with cancer, with a particular focus on childhood cancer. This chart shows the average market value for the sector, helping to understand how the market views the company's focus on underserved patient groups.
P/E of the market as a whole
Day One Biopharmaceuticals is focused on developing cancer treatments for children and young adults. This is an important but narrow niche. Does the company's valuation exist in its own world of clinical data and regulatory decisions, or does the overall market appetite for risk, as reflected in this chart, influence investors' willingness to fund such socially significant but risky projects?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Day One
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages, with a particular focus on pediatric oncology. This chart reflects investor confidence in the potential of its drugs. Future revenue depends on the success of clinical trials and regulatory approval.
%20P%2FE%20Day%20One&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Day-One&v=1772513418670 "Chart of the company's future (projected) P/E Day One")
Future (projected) P/E of the market segment - General oncology therapy
Day One Biopharmaceuticals aims to develop and commercialize targeted therapies for the treatment of cancer in patients of all ages, with a particular focus on pediatric oncology. This chart shows forecasts for the oncology sector, allowing investors to compare their faith in Day One's scientific approach and drug portfolio with the overall sentiment in this highly competitive field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772513418734 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Day One Biopharmaceuticals is focused on developing cancer treatments for children and adolescents. This is a socially significant but complex niche. The company's valuation depends on the success of its clinical programs. This chart of overall risk appetite shows how willing investors are to back biotech companies with a narrow but important focus.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513418773 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Day One
Day One Biopharmaceuticals is focused on developing drugs to treat cancer in children and adults with genetic mutations. The company is in the clinical stage. This chart illustrates the financial implications of targeted oncology: significant investments in research and development to create drugs for specific patient groups.
Profit of companies in the market segment - General oncology therapy
Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for cancer treatment in patients of all ages, with a particular focus on pediatric oncology. This chart, showing the pharmaceutical sector's profitability, reflects the investment environment. For a company solving complex problems in oncology, the sector's health provides access to capital for vital research.
Overall market profit
Day One Biopharmaceuticals is focused on developing cancer treatments for children and young adults. This is a socially significant yet complex niche. Funding for such projects is highly dependent on overall market conditions. Growing corporate profits, as shown in this chart, create a favorable investment climate, allowing companies like Day One to attract capital for vital research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Day One
Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for cancer treatment in patients of all ages, with a particular focus on pediatric oncology. This chart summarizes analysts' predictions for clinical trial success and potential demand for their life-changing drugs.
%20profit%20of%20the%20company%20Day%20One&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Day-One&v=1772513418830 "Graph of future (projected) profit of the company Day One")
Future (predicted) profit of companies in the market segment - General oncology therapy
Day One Biopharmaceuticals focuses on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages, beginning with children. Its success depends on clinical results and regulatory approval. This chart for the oncology sector illustrates the overall expectations for innovative treatments and the growth potential for companies working in this field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772513418842 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Day One Biopharmaceuticals is focused on developing treatments for childhood and adolescent cancer. Its operations are primarily driven by scientific advances. However, the overall economic climate reflected by this chart influences the flow of philanthropic and investment capital into the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513418847 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Day One
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for cancer patients of all ages. This chart is crucial because it shows investors' assessment of potential future sales. It reflects the company's expectations for the success of its drugs for the treatment of difficult-to-treat cancers in children and adults.
P/S market segment - General oncology therapy
Day One Biopharmaceuticals focuses on developing and commercializing targeted therapies for pediatric and adult cancers. The company's valuation is based on the potential of its drugs to address critical medical needs. This chart, which displays the average oncology valuation, provides context for understanding how the market views Day One's mission and science.
P/S of the market as a whole
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages, with a particular focus on pediatric oncology. This chart, showing revenue estimates for real businesses, highlights that Day One's market capitalization is based on the hope that its drugs will transform the lives of patients with rare and difficult-to-treat cancers.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Day One
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for the treatment of pediatric and adult cancers. Its valuation is based on future potential. This chart reflects investor expectations for successful clinical trials and the commercialization of drugs that could transform cancer treatment.
%20P%2FS%20Day%20One&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Day-One&v=1772513418889 "The graph of the company's future (projected) P/S Day One")
Future (projected) P/S of the market segment - General oncology therapy
Day One Biopharmaceuticals is a commercial biopharmaceutical company focused on developing and commercializing targeted therapies for patients of all ages with genetically modified cancers. This chart reflects average revenue expectations in the oncology sector, allowing one to assess the market's perception of the potential of Day One's drugs.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772513418897 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for pediatric and adult cancers. This chart reflects market expectations for future revenue overall. The company's progress in creating drugs for rare and difficult-to-treat cancers fuels investor optimism that science can conquer the most complex diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513418922 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Day One
This chart illustrates the revenue of Day One Biopharmaceuticals, a company focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages, with a particular focus on pediatric oncology. Sales trends reflect the successful launch of its drugs and their acceptance by the medical community for the treatment of rare cancers.
Sales of companies in the market segment - General oncology therapy
Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages, with a particular focus on pediatric oncology. This chart reflects the growth of the oncology market. The company strives to accelerate access to innovative medicines for children, occupying a unique and socially significant niche in the industry.
Overall market sales
Day One Biopharmaceuticals is focused on developing treatments for pediatric and adult cancers. The company is in clinical trials. Its funding is dependent on the biotech market, which is indirectly influenced by the overall economic situation, as shown in this chart.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Day One
Day One Biopharmaceuticals is focused on developing cancer treatments for patients of all ages, including children. Its revenue forecast is based on expectations of successful clinical trials. The chart reflects analysts' confidence in the commercial potential of its targeted therapies.
%20sales%20of%20the%20company%20Day%20One&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Day-One&v=1772513419050 "Schedule of future (projected) sales of the company Day One")
Future (projected) sales of companies in the market segment - General oncology therapy
Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages, with a particular focus on pediatric oncology. This chart shows the forecast for the overall oncology market, where Day One aims to fill an important niche by offering new hope to vulnerable patient groups.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772513419159 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Day One Biopharmaceuticals specializes in developing cancer treatments for children and young adults. The company's mission defines its focus on a specific but important niche. This chart illustrates the overall investment climate, but Day One's funding also depends on social demand for treatments for childhood diseases and support from patient organizations and foundations.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513419186 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Day One
Day One Biopharmaceuticals is focused on developing drugs to treat cancer in children and young adults. While in the clinical stage, the company incurs significant R&D expenses. This chart reflects its losses—investing in a crucial, yet often neglected, area of oncology. This is an attempt to create breakthrough treatments for the youngest patients.
Market segment marginality - General oncology therapy
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages. Profitability depends on the success of their drugs. This chart shows their operating results as they pursue growth. A comparison with other oncology companies highlights their focus on innovative treatments.
Market marginality as a whole
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages, with a particular focus on pediatric oncology. This chart, which shows the company's overall financial situation, is not definitive. Their success depends solely on the results of clinical trials and regulatory approval of their drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Day One
Day One Biopharmaceuticals is a company focused on developing targeted cancer therapies for children and adults. Its team is small, but it is growing as its lead drug advances through clinical trials. The growth on this chart signals its transformation from a research-based company to a commercial one.
Share of the company's employees Day One within the market segment - General oncology therapy
Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for the treatment of pediatric and adult cancers. This chart reflects the company's share of the total number of specialists in this important area of oncology. This growth reflects the expansion of its clinical programs and the company's commitment to bringing new treatment options to patients as quickly as possible.
Number of employees in the market segment - General oncology therapy
Day One Biopharmaceuticals focuses on the development and commercialization of targeted therapies for the treatment of cancer in patients of all ages. This chart shows the employment dynamics in the precision oncology sector. The growing number of scientists and clinicians in this field reflects advances in understanding the genetic basis of cancer and the desire to create more effective and less toxic drugs.
Number of employees in the market as a whole
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for cancer treatment in patients of all ages, with a particular focus on pediatric oncology. Its mission is to accelerate access to innovative medicines. This indicator demonstrates how biotech companies operating in socially significant niches stimulate scientific research and employment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Day One (DAWN)
Day One Biopharmaceuticals focuses on developing treatments for pediatric and adult cancers. This chart is a classic example of valuing intellectual capital in biotech. The company has an approved drug, and the market is evaluating its potential. The chart shows this high market value (based on IP and future sales) per employee.
%20of%20the%20company%20Day%20One%20(DAWN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Day-One-DAWN&v=1772513419426 "Chart of market capitalization per employee (in thousands of dollars) of the company Day One (DAWN)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Day One Biopharmaceuticals focuses on developing cancer treatments for children and young adults. It is a highly specialized biotech company with a strong social mission. Its value is determined by the potential of its drugs. This chart shows the high valuation of its scientific developments, based on its small but highly motivated team.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772513419431 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Day One Biopharmaceuticals is a company focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages. The chart reflects the valuation of a company with a promising drug. The high cost per employee indicates that the market is pricing in future revenue from sales of this important drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513419447 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Day One (DAWN)
Day One Biopharmaceuticals is a biotech company focused on developing cancer treatments for children and young adults. It's an R&D company with a strong social mission. This chart shows the cost of that mission: the amount of investment the company makes for each scientist working on clinical trials for relatively small patient groups.
%20Chart%20Day%20One%20(DAWN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Day-One-DAWN&v=1772513419515 "Company Profit Per Employee (in thousands of dollars) Chart Day One (DAWN)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Day One Biopharmaceuticals (DAWN) is a company focused on developing cancer drugs for children and adolescents. This is a niche but important area of oncology. Like other R&D companies, this metric is negative, reflecting the cost of conducting complex clinical trials.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772513419567 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Day One (DAWN) is a biotech company focused on pediatric oncology. They have an approved drug (Ojemda). This chart is intended to show the transition from R&D losses to profitability. It reflects how successfully the company's commercial team is bringing this niche but important drug to market, per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513419594 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Day One (DAWN)
Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for the treatment of cancer in patients of all ages. This graph indicates the commercial potential of its research and development efforts. Increasing revenue per employee will indicate successful drug launches and increased demand in oncology practice.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Day-One-DAWN&v=1772513419624 "Sales chart per company employee Day One (DAWN)")
Sales per employee in the market segment - General oncology therapy
Day One Biopharmaceuticals focuses on developing cancer drugs for children and young adults—a critical but challenging niche. This chart shows how productive their research team is. It measures revenue (possibly from partnerships) per researcher, comparing them to other companies in the oncology therapeutics segment.
Sales per employee for the market as a whole
Day One (DAWN) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment in patients of all ages, starting with children. The company is in the clinical stage. This chart illustrates a classic R&D situation: the company has no commercial revenue yet, but its entire staff of scientists and doctors is working on the development of its future product.
Short shares by company, segment and market as a whole
Shares shorted by company Day One (DAWN)
Day One is a biotech company focused on developing treatments for pediatric and adult cancers with genetic mutations. This is a niche but important area. This chart suggests bearish bets. Investors may be skeptical about the size of the target market for its drugs or the success of its late-stage clinical programs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Day-One-DAWN&v=1772513419661 "Short Shares Chart for the Company Day One (DAWN)")
Shares shorted by market segment - General oncology therapy
Day One Biopharmaceuticals is a company focused on treating cancer in children and adolescents. Their first drug (Toforutinib) targets pediatric brain tumors. This indicator reflects skepticism. "Short" here is a bet that their drug will fail to live up to expectations or that its market potential is too small.
Shares shorted by the overall market
Day One Biopharmaceuticals focuses on developing pediatric oncology drugs. This is a socially important but risky area. When this chart shows rising general fear, investors flee biotech without profits. For DAWN, this means that positive drug news must be very strong to outweigh the overall negativity.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Day One (DAWN)
Day One (DAWN) is a biopharmaceutical company focused on pediatric oncology. Their lead drug is designed to treat brain tumors in children. It's a high-impact, binary-risk business. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) during periods of anticipation.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Day-One-DAWN&v=1772513419765 "RSI 14 indicator chart for the company's stock Day One (DAWN)")
RSI 14 Market Segment - General oncology therapy
Day One (DAWN) is a biotech company focused on the "most challenging" field—treating childhood cancer (pediatric oncology). The RSI_14_Seg for "Oncology" (biotech) shows the overall sentiment. The chart helps us understand: is DAWN's volatility a reaction to its clinical trials, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
Day One (DAWN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DAWN (Day One)
Day One Biopharmaceuticals (DAWN) is a company focused on developing targeted therapies for the treatment of pediatric and adult cancers. Its first drug has been approved for the treatment of a rare pediatric brain tumor. This chart shows the average analyst forecast. Their price targets are based on the success of this launch and the potential of their drugs for other cancer types.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DAWN-Day-One&v=1772513419817 "A chart showing analyst consensus forecasts for the expected stock price. DAWN (Day One)")
The difference between the consensus estimate and the actual stock price DAWN (Day One)
Day One (DAWN) is a pediatric oncology-focused biotech whose first drug (Ojemda) received accelerated approval for the treatment of pediatric brain tumors. This chart is a barometer of their commercialization. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their first drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DAWN-Day-One&v=1772513419832 "A chart showing the difference between the consensus forecast and the actual stock price. DAWN (Day One)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Day One Biopharmaceuticals (DAWN) is a company focused on treating childhood cancer. Its first drug, Ojemda, was approved for the treatment of pediatric brain tumors. This chart shows overall expectations for the general oncology sector. It reflects whether experts believe drugs for rare pediatric diseases will be commercially successful.
Analysts' consensus forecast for the overall market share price
Day One (DAWN) is a biopharmaceutical company focused on pediatric oncology. They develop targeted therapies for the treatment of cancer in children and adolescents, an area with a huge unmet need. This chart shows the overall risk appetite, reflecting the willingness of investors to fund complex and socially significant R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Day One
Day One Biopharmaceuticals is a biotech company focused on pediatric oncology. Their mission is to accelerate the development of cancer drugs specifically for children. Their first drug (Ojemda) has already been approved. This timeline is a barometer of their launch. It likely reflects the pace of commercialization of their first drug and the market's confidence in their R&D pipeline, which is focused on this niche.
AKIMA Market Segment Index - General oncology therapy
Day One (DAWN) is a clinical-stage biotech focused on pediatric oncology; the company is developing targeted drugs (Toforstumab) for the treatment of pediatric brain cancer. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (children) R&D focus (DAWN) differentiate it from the average pharma company?
The AKIM Index for the overall market
Day One Biopharmaceuticals is a company developing targeted cancer treatments for children and adults. Its key drug is Ojemda. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this commercial biotech story in a rare niche compares to the overall economic trends affecting the healthcare sector.
